| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Lefamulin acetate (USAN); Xenleta (TN) | ||||||
| Product | ANHYDROUS CITRIC ACID (Nabriva Therapeutics US) | ||||||
| Formula | C28H45NO5S. C2H4O2 | ||||||
| Exact mass | 567.323 | ||||||
| Mol weight | 567.7776 | ||||||
| Structure |  | ||||||
| Class | Antibacterial DG01813 Pleuromutilin Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate | ||||||
| Remark |
| ||||||
| Efficacy | Antibacterial, Protein biosynthesis inhibitor | ||||||
| Comment | Pleuromutilin [CPD:C09169] derivative Treatment of community-acquired bacterial pneumonia (CABP) | ||||||
| Target | 50S ribosomal subunit | ||||||
| Metabolism | Enzyme: CYP3A4 [HSA:1576] | ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] J ANTIINFECTIVES FOR SYSTEMIC USE J01 ANTIBACTERIALS FOR SYSTEMIC USE J01X OTHER ANTIBACTERIALS J01XX Other antibacterials J01XX12 Lefamulin D11632 Lefamulin acetate (USAN) <US> USP drug classification [BR:br08302] Antibacterials Antibacterials, Other Lefamulin D11632 Lefamulin acetate (USAN) Drug groups [BR:br08330] Antibacterial DG01813 Pleuromutilin DG03066 Lefamulin D11632 Lefamulin acetate Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG03066 Lefamulin D11632 Lefamulin acetate Antimicrobials [BR:br08307] Antibacterials Protein biosynthesis inhibitor Pleuromutilin D11632 Lefamulin acetate (USAN) <US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11632 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11632 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D11632 Drug groups [BR:br08330] Antibacterial DG01813 Pleuromutilin DG03066 Lefamulin Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG03066 Lefamulin Antimicrobials abbreviations [BR:br08327] Antibacterials Protein biosynthesis inhibitor Pleuromutilin DG03066 Lefamulin | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 39 1 C1z C 24.5833 -16.8791 2 C1y C 23.6027 -17.8596 3 C1y C 24.5833 -15.4784 4 C1x C 25.8439 -17.5094 5 C1x C 24.5833 -18.3499 6 C1z C 22.2020 -17.8596 7 C5x C 24.2331 -19.1203 8 C1y C 23.6027 -14.4978 9 C1a C 25.8439 -14.9180 10 C1x C 25.5638 -18.9102 11 C1x C 23.2525 -18.2799 12 C1y C 21.1514 -16.8791 13 C1y C 22.1319 -19.2604 14 C1a C 21.2915 -18.9102 15 O5x O 23.6027 -20.3810 16 C1z C 22.2020 -14.4978 17 O1a O 24.0930 -13.1671 18 C1x C 21.1514 -15.4784 19 O7a O 19.8907 -17.3694 20 C1a C 21.7818 -20.5911 21 C7a C 18.6301 -16.6690 22 C1b C 17.4394 -17.3694 23 O6a O 18.6301 -15.2682 24 S2a S 16.2488 -16.6690 25 C1y C 15.0581 -17.3694 26 C2b C 21.6417 -13.1671 27 C1a C 20.8012 -14.4978 28 C2a C 21.6417 -11.8364 29 C1x C 15.0581 -18.7701 30 C1x C 13.8675 -19.4705 31 C1y C 12.6768 -18.7701 32 C1x C 12.6768 -17.3694 33 C1y C 13.8675 -16.6690 34 O1a O 13.8675 -15.2682 35 N1a N 11.4862 -19.4705 36 C6a C 29.8200 -18.6900 37 C1a C 31.0324 -19.3900 38 O6a O 28.6076 -19.3900 39 O6a O 29.8200 -17.2900 BOND 41 1 3 8 1 2 3 9 1 #Down 3 4 10 1 4 5 11 1 5 6 12 1 6 6 13 1 7 6 14 1 #Down 8 7 15 2 9 8 16 1 10 8 17 1 #Up 11 12 18 1 12 12 19 1 #Down 13 13 20 1 #Up 14 19 21 1 15 21 22 1 16 21 23 2 17 22 24 1 18 7 10 1 19 11 13 1 20 16 18 1 21 25 24 1 #Down 22 1 2 1 23 1 3 1 24 1 4 1 25 1 5 1 #Up 26 2 6 1 27 2 7 1 28 16 26 1 #Up 29 16 27 1 #Down 30 26 28 2 31 25 29 1 32 29 30 1 33 30 31 1 34 31 32 1 35 32 33 1 36 25 33 1 37 33 34 1 #Up 38 31 35 1 #Up 39 36 37 1 40 36 38 1 41 36 39 2 |